The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (Delta GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases.

被引：0
|
作者：
Ruggenenti, P [1 ]
Perna, A [1 ]
Mosconi, L [1 ]
Matalone, M [1 ]
Gaspari, F [1 ]
Garini, G [1 ]
Salvadori, M [1 ]
Zoccali, C [1 ]
Scolari, F [1 ]
Maggiore, Q [1 ]
Tognoni, G [1 ]
Remuzzi, G [1 ]
机构：
[1] MARIO NEGRI INST PHARMACOL RES,GISEN,I-24100 BERGAMO,ITALY
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 1997年 / 8卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A0696 / A0696
页数：1
相关论文
共 14 条
  • [1] In non-diabetic chronic nephropathies, hypertension and proteinuria are the strongest predictors of GFR decline (Delta GFR) and progression to end stage renal failure (ESRF).
    Perna, A
    Remuzzi, G
    Ruggenenti, P
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A0692 - A0692
  • [2] Spot morning urine protein to creatinine (P/C) ratio correlates with 24-hour proteinuria and predict rate of GFR decline (Delta GFR) and progression to end stage renal failure (ESRF) in non-diabetic chronic nephropathies.
    Matalone, M
    Gaspari, F
    Ruggenenti, P
    Perna, A
    Remuzzi, G
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A0681 - A0681
  • [3] Effects of angiotensin-converting-enzyme inhibitors on progression to end-stage renal failure in chronic vascular rejection
    Rustom, R
    Paraoan, MT
    Sells, RA
    Jackson, MJ
    Hammad, A
    Bakran, A
    Brown, M
    Ahmad, RA
    Williams, PS
    Bell, GM
    Sharma, A
    Bone, JM
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 1175 - 1176
  • [4] In non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure (ESRF).
    Ruggenenti, P
    Perna, A
    Lanzoni, M
    Remuzzi, G
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A0390 - A0390
  • [5] Association between angiotensin-converting enzyme (ACE) gene polymorphism and failure of renoprotective therapy in non-diabetic chronic renal failure.
    vanEssen, GG
    Rensma, PL
    deZeeuw, D
    Sluiter, WJ
    Scheffer, H
    Apperloo, AJ
    deJong, PE
    KIDNEY INTERNATIONAL, 1996, 50 (01) : 331 - 331
  • [6] Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease. Results of COOPERATE
    Lyakishev, AA
    KARDIOLOGIYA, 2003, 43 (09) : 76 - 76
  • [7] Enalapril, angiotensin-converting enzyme inhibitor, effects on progression rate of chronic renal failure in patients with renal dysfunction of different degree
    Esayan, AM
    Kayukov, IG
    Titova, VA
    TERAPEVTICHESKII ARKHIV, 1995, 67 (06) : 57 - 59
  • [8] Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
    Ruggenenti, P
    Perna, A
    Mosconi, L
    Matalone, M
    Garini, G
    Salvadori, M
    Zoccali, C
    Scolari, F
    Maggiore, Q
    Tognoni, G
    Remuzzi, G
    Migone, L
    Marubini, E
    DelFavero, A
    Ideo, G
    Geraci, E
    Loi, U
    Bracchi, M
    Costantino, E
    Scolari, F
    Maiorca, R
    Cofano, F
    Fellin, G
    DAmico, G
    Dissegna, D
    Brendolan, A
    LaGreca, G
    Feriozzi, A
    Ancarani, E
    Gandini, E
    dAmato, I
    Giangrande, A
    Garneri, G
    Giacchino, F
    Giannico, G
    Giotta, N
    Vitale, O
    Manno, C
    Mazzi, A
    Garini, G
    Borghetti, A
    Pisoni, R
    Bertani, T
    Novelli, R
    Scanferla, F
    Bazzato, G
    Oliva, E
    Zoccali, C
    Pieri, F
    Sisca, S
    LANCET, 1997, 349 (9069): : 1857 - 1863
  • [9] Effects of spironolactone (SPL) on proteinuria and renal function in normotensive patients with non-diabetic renal disease treated with angiotensin-converting-enzyme inhibitor(ACEI) and angiotensin II receptor blocker(ARB)
    Ogawa, Tetsuya
    Ichikawa, Akiko
    Matsuda, Nami
    Fujiu, Ayuko
    Nitta, Kosaku
    JOURNAL OF HYPERTENSION, 2006, 24 : 344 - 344
  • [10] Polymorphism of the angiotensin I converting enzyme (ACE) gene does not predict disease progression, nor response to ACE-inhibition in non-diabetic chronic renal disease.
    Zoccali, C
    Misefari, V
    Romeo, G
    Testa, A
    Spoto, B
    Ruggenenti, P
    Perna, A
    Matalone, M
    Remuzzi, G
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A0385 - A0385
12